Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.
We compared functional imaging modalities including PET with 6-(18)F-fluorodopamine ((18)F-DA) with (123)I-metaiodobenzylguanidine ((123)I-MIBG) and somatostatin receptor scintigraphy (SRS) with (111)In-pentetreotide in nonmetastatic and metastatic pheochromocytoma (PHEO).


METHODS
We studied 25 men and 28 women (mean age +/- SD, 44.2 +/- 14.2 y) with biochemically proven nonmetastatic (n = 17) or metastatic (n = 36) PHEO. Evaluation included anatomic imaging with CT or MRI and functional imaging that included at least 2 nuclear medicine modalities: (18)F-DA PET, (123)I-MIBG scintigraphy, or SRS. Sensitivity of functional imaging versus anatomic imaging was assessed on a per-patient and a per-region basis.


RESULTS
For this available cohort, on a per-patient basis overall sensitivity (combined for nonmetastatic and metastatic PHEO) was 90.2% for (18)F-DA PET, 76.0% for (123)I-MIBG scintigraphy, and 22.0% for SRS. On a per-region basis, overall sensitivity was 75.4% for (18)F-DA PET, 63.4% for (123)I-MIBG scintigraphy, and 64.0% for SRS.


CONCLUSIONS
If available, (18)F-DA PET should be used in the evaluation of PHEO, because it is more sensitive than (123)I-MIBG scintigraphy or SRS. If (18)F-DA PET is not available, (123)I-MIBG scintigraphy (for nonmetastatic or adrenal PHEO) and SRS (for metastatic PHEO) should be the first alternative imaging methods to be used.
Ilias
Ioannis
I
Reproductive Biology and Adult Endocrinology Program, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-1109, USA.
Chen
Clara C
CC
Carrasquillo
Jorge A
JA
Whatley
Millie
M
Ling
Alexander
A
Lazúrová
Ivica
I
Adams
Karen T
KT
Perera
Shiromi
S
Pacak
Karel
K
D019797:3-Iodobenzylguanidine; D003952:Diagnostic Imaging / Q000379:methods; D004298:Dopamine / Q000031:analogs & derivatives*; D005260:Female; D005462:Fluorine Radioisotopes; D006801:Humans; D007205:Indium Radioisotopes / Q000494:pharmacology*; D007457:Iodine Radioisotopes; D008297:Male; D009362:Neoplasm Metastasis; D010673:Pheochromocytoma / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods*; D011877:Radionuclide Imaging / Q000379:methods*; D019275:Radiopharmaceuticals; D012189:Retrospective Studies
D005462:Fluorine Radioisotopes; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine; C029253:6-fluorodopamine; D004298:Dopamine
N Engl J Med. 1999 Jun 17;340(24):1872-9
10369850
J Nucl Med. 2003 Nov;44(11):1767-74
14602858
Radiology. 2002 Feb;222(2):507-12
11818620
Endocr Rev. 1994 Jun;15(3):356-68
8076587
J Clin Endocrinol Metab. 2004 Feb;89(2):479-91
14764749
Clin Nucl Med. 2000 Jun;25(6):440-2
10836692
Horm Metab Res. 2005 Dec;37(12):722-8
16372224
J Nucl Med. 1992 Jun;33(6):1125-31
1597727
Anticancer Res. 1997 May-Jun;17(3B):1589-92
9179199
Laryngoscope. 2004 Mar;114(3):434-40
15091215
Eur J Nucl Med Mol Imaging. 2003 May;30(5):689-94
12618904
Q J Nucl Med. 1995 Dec;39(4 Suppl 1):3-8
9002740
Ann Intern Med. 1995 Jul 15;123(2):101-9
7778821
Exp Clin Endocrinol Diabetes. 1998;106(5):373-6
9831301
Q J Nucl Med. 1995 Dec;39(4 Suppl 1):145-9
9002775
Radiology. 2004 Feb;230(2):423-8
14752186
Q J Nucl Med. 1996 Dec;40(4):365-71
9050342
Eur J Nucl Med. 2001 Sep;28(9):1421-9
11585303
Hypertension. 2001 Jul;38(1):6-8
11463751
J Clin Endocrinol Metab. 2001 Feb;86(2):685-93
11158032
Endocr Relat Cancer. 2006 Jun;13(2):525-33
16728579
Ann Intern Med. 2001 Feb 20;134(4):315-29
11182843
J Clin Endocrinol Metab. 2001 Feb;86(2):895-902
11158063
Clin Nucl Med. 1995 Mar;20(3):243-9
7750219
Radiology. 1999 Jul;212(1):35-41
10405717
J Postgrad Med. 1994 Apr-Jun;40(2):85-7
8737560
Nucl Med Commun. 2006 Jan;27(1):31-6
16340721
Eur J Surg. 2001 Nov;167(11):866-70
11848244
Nucl Med Commun. 2006 Jul;27(7):583-7
16794519
J Clin Oncol. 2007 Jun 1;25(16):2262-9
17538171
Endocrine. 2003 Apr;20(3):307-11
12721512
Clin Nucl Med. 2005 Aug;30(8):579-81
16024963
Int J Urol. 1999 Mar;6(3):119-24
10226821
J Nucl Med. 2007 Dec;48(12):1940-4
18006611
Endocr Rev. 2004 Aug;25(4):568-80
15294882
Eur J Endocrinol. 1999 Dec;141(6):619-24
10601965
J Clin Endocrinol Metab. 2001 Aug;86(8):3641-6
11502790
Endocr Res. 2004 Nov;30(4):931-4
15666847
AJNR Am J Neuroradiol. 1997 Jun-Jul;18(6):1073-80
9194434
J Nucl Med. 1995 Jan;36(1):1-6
7799058
Eur J Nucl Med. 1993 Aug;20(8):716-31
8404961
Clin Nucl Med. 1996 Sep;21(9):695-9
8879869
Am J Med. 1987 Oct;83(4):770-2
3674064
Fam Cancer. 2005;4(1):61-8
15883712
Q J Nucl Med. 1999 Sep;43(3):217-23
10568137
Ann Surg Oncol. 2006 Feb;13(2):187-97
16418883
J Clin Endocrinol Metab. 2003 Sep;88(9):4083-7
12970267